Biotech Strategy Blog

Commentary on Science, Innovation & New Products

EORTC Molecular Targets – new developments in Ovarian Cancer

Ovarian cancer is an often neglected area in cancer drug development and historically has often been one of the last solid tumours to be evaluated as part of a life cycle management program. There are a number of reasons for this, but recently that situation has begun to change as our knowledge of the underlying biology improves and new agents are developed that target the particular oncogenic aberrations.

Leave a comment